Topiramate NDC 51407-893

NDC codes

FDA NDC Directory

Product NDC (as listed)51407-893Labeler and product segments. Claims need a package NDC.

Product NDC at billing width51407-0893Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
51407-893-60	51407089360	60 CAPSULE in 1 BOTTLE, PLASTIC (51407-893-60)Marketed from Mar 19, 2024

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Topiramate
Generic name (nonproprietary): topiramate
Active ingredients: Topiramate — 15 mg/1
Dosage form: Capsule
Route: Oral
Labeler: Golden State Medical Supply, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 217694
Marketing start: Dec 5, 2023
Listing expires: Dec 31, 2027
Other FDA classes: Cytochrome P450 2C19 Inhibitors (Mechanism)Cytochrome P450 3A4 Inducers (Mechanism)Decreased Central Nervous System Disorganized Electrical Activity (Physiologic effect)
Identifiers: Product ID 51407-893_55069b30-2f93-2d4f-e063-6294a90ae7a6SPL ID 55069b30-2f93-2d4f-e063-6294a90ae7a6SPL set ID 163e9f2d-27be-6d3f-e063-6394a90a5884RxCUI 205315, 205316UNII 0H73WJJ391

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N451407089360 followed by a unit qualifier and the quantity

Package 51407-0893-60. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 24, 2026.

Indications (excerpt from the label)

Topiramate capsules are indicated for: Epilepsy: initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older (1.1); adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome in patients 2 years of age and older (1.2) Preventive treatment of migraine in patients 12 years of age and older (1.3) 1.1 Monotherapy Epilepsy Topiramate capsules are indicated as initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older. 1.2 Adjunctive Therapy Epile…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 217694

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 217694
Product	Strength	Form · route	Labeler	Product NDC
Topiramate	Topiramate 15 mg/1	CapsuleOral	Upsher-Smith Laboratories, LLC	24979-210
Topiramate	Topiramate 25 mg/1	CapsuleOral	Upsher-Smith Laboratories, LLC	24979-211
Topiramate	Topiramate 25 mg/1	CapsuleOral	Golden State Medical Supply, Inc.	51407-894